Abstract
Bronchiectasis, particularly in children, is an increasingly recognised yet neglected chronic lung disorder affecting individuals in both low-to-middle and high-income countries. It has a high disease burden and there is substantial inequity within and between settings. Furthermore, compared with other chronic lung diseases, considerably fewer resources are available for children with bronchiectasis. The need to prevent bronchiectasis and to reduce its burden also synchronously aligns with its high prevalence and economic costs to health services and society. Like many chronic lung diseases, bronchiectasis often originates early in childhood, highlighting the importance of reducing the disease burden in children. Concerted efforts are therefore needed to improve disease detection, clinical management and equity of care. Modifiable factors in the causal pathways of bronchiectasis, such as preventing severe and recurrent lower respiratory infections should be addressed, whilst also acknowledging the role played by social determinants of health. Here, we highlight the importance of early recognition/detection and optimal management of bronchiectasis in children, and outline our research, which is attempting to address important clinical knowledge gaps discussed in a recent workshop. The research is grouped under three themes focussing upon primary prevention, improving diagnosis and disease characterisation, and providing better management. Our hope is that others in multiple settings will undertake additional studies in this neglected field to further improve the lives of people with bronchiectasis. We also provide a resource list with links to help inform consumers and healthcare professionals about bronchiectasis and its recognition and management.
Original language | English |
---|---|
Pages (from-to) | 364-373 |
Number of pages | 10 |
Journal | Archivos de Bronconeumologia |
Volume | 60 |
Issue number | 6 |
Early online date | 2024 |
DOIs | |
Publication status | Published - Jun 2024 |
Bibliographical note
Funding Information:The workshop was supported by a National Health and Medical Research Council (NHMRC) Centre of Research Excellence (CRE) grant for paediatric bronchiectasis, especially in Aboriginal and Torres Strait Islanders grant (GNT1170958). ABC (L3, GNT2025379) and SCD are supported by NHMRC Investigator fellowships. JMM, STY and DFW are supported by NHMRC CRE (GNT1170958) fellowships. AS is supported by a Medical Research Future Fund (MRFF) Fellowship (APP1193796).
Funding Information:
ABC, STY, SCD, KG, AS, PSM, MT, GBM and JMM report grants from the NHMRC and NHMRC managed grants (MRFF), Australia, during the conduct of the CRE. ABC is also an independent data management committee member for clinical trials for Moderna (COVID-19 vaccine) and of an unlicensed vaccine (GlaxoSmithKline), and monoclonal antibody (AstraZeneca), received fees to the institution for consulting on study designs for Zambon and Boehringer Ingelheim, and personal fees for being an author of two UpToDate chapters. SCD holds an investigator-initiated grant from GlaxoSmithKline and AstraZeneca for unrelated research. AS has received honoraria as advisory board member for Vertex Pharmaceuticals. All other authors have nothing to declare.
Publisher Copyright:
© 2024 The Authors